Reviewing Abeona Therapeutics (NASDAQ:ABEO) & Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and target prices for Pharming Group and Abeona Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2	0	3	0	2.20
Abeona Therapeutics	1	0	2	0	2.33

Pharming Group presently has a consensus target price of $38.67, indicating a potential upside of 257.36%. Abeona Therapeutics has a consensus target price of $19.33, indicating a potential upside of 256.05%. Given Pharming Group’s higher possible upside, equities analysts plainly believe Pharming Group is more favorable than Abeona Therapeutics.

Profitability

This table compares Pharming Group and Abeona Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Valuation & Earnings

This table compares Pharming Group and Abeona Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13 million	2.04	$2.85 million	$0.12	90.17
Abeona Therapeutics	$25.52 million	12.17	$71.18 million	($1.09)	-4.98

Abeona Therapeutics has lower revenue, but higher earnings than Pharming Group. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Pharming Group has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Summary

Pharming Group beats Abeona Therapeutics on 8 of the 14 factors compared between the two stocks.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

About Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.